A Phase 1/2a Study Investigating TAK-079 Administered Subcutaneously in Patients With Relapsed/Refractory Multiple Myeloma

Trial Overview

Am I Eligible?

Participating US Centers

Weill Cornell Medicine

This center is currently accepting patients.

New York, NY


City of Hope Comprehensive Cancer Center
Beckman Research Institute

This center is currently accepting patients.

Duarte, CA


MD Anderson Cancer Center
The University of Texas

This center is currently accepting patients.

Houston, TX


Medical College of Wisconsin
Froedtert Hospital

This center is currently accepting patients.

Milwaukee, WI


Siteman Cancer Center
Washington University Medical Campus

This center is currently accepting patients.

St. Louis, MO


Mount Sinai Hospital
Tisch Cancer Institute

This center is currently accepting patients.

New York, NY


Oregon Health and Science University (OHSU)
Knight Cancer Institute

This center is currently accepting patients.

Portland, OR


Virginia Cancer Specialists

This center is currently accepting patients.

Fairfax, VA


Texas Oncology
San Antonio Northeast

This center is currently accepting patients.

San Antonio, TX

ACCEPTING

This trial is currently open and accepting patients.



Additional Information
Trial Phase

Phase 1/2

Trial Enrollment

42 sparks required

Trial Sponsors
  • Takeda Oncology
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;